We then created a single EQ-5D-3L index value for the HRQOL (0-1, worst to best health; Appendix Table 4 ) (11) . We divided time into day-ranges (0-6, 7-15, 16-30, 31-60, 61-120, and 121-180) because not all participants responded to the questionnaires on the exact same days.
We analyzed changes in HRQOL over time using survival and Cox regression analyses. We defined recovery as baseline HRQOL (before DENV infection) and calculated the time it took each patient to recover. We estimated HRQOL recovery time for subgroups of patients using Kaplan-Meier with log-rank test statistic and identified significant predictors of HRQOL using Cox regression analyses.
The final sample comprised 62% ambulatory and 38% hospitalized patients. Most participants (retrospectively) reported no symptoms before dengue onset. The most affected domains were pain/discomfort, usual activities, and mobility. Almost all participants reported some/extreme problems during the first 6 days (92% pain/discomfort, 87% usual activities, 80% mobility). The proportion of participants reporting problems in any domain increased at 7-15 days after fever onset and remained largely stable until day 30 (Table 1) Health-related quality of life was assessed by an adapted EQ-5D-3L questionnaire (Appendix Table 3 , https://wwwnc.cdc.gov/EID/article/26/4/19-0729-App1.pdf) for reporting of problems after 1 month since fever onset (i.e., days 31-60, 61-120, 121-180). average of 46.7 days to completely recover their baseline HRQOL. We also assessed participants' self-reported health status (EQ-VAS) during the first 6 days ( (Figure 1,  panel B ), mean EQ-VAS was 38.1 (95% CI 33.8-42.5) for days 1-6, the lowest observed for any day range. The mean EQ-VAS score then improved until days 61-120 (EQ-VAS 90.4 [95% CI 84.5-96.3]), when it no longer differed significantly from baseline (α = 0.05).
We assessed the mean EQ-5D index score before DENV infection (baseline) and during the first 6 days of illness (Figure 2, panel A) . Participants showed high baseline scores (EQ-VAS 0.98 [95% CI 0.96-0.99]). The mean EQ-5D index score dropped by >50% to 0.48 (95% CI 0.42-0.49) during the first day and was 0.57 (95% CI 0.46-0.69) on day 6. During the course of the study period, the EQ-VAS was low during the first 6 days (0.53 [95% CI 49-0.58]) and increased to 0.85 (95% CI 0.80-0.89) for days 7-15 (Figure 2, panel B) .
The index EQ-VAS did not differ significantly from baseline after ≈61 days (0.92 [95% CI 0.88-0.98]).
We tested differences in HRQOL recovery time using Kaplan-Meier curves for individual subgroups (Appendix Figure 1 ). Survival curves showed slower recovery times for hospitalized participants (≈40% recovered baseline HRQOL) than for ambulatory participants (≈75%) after 30 days (p = 0.012). Participants with severe symptoms (≈30%) also showed slower recovery than did participants without severe symptoms (≈75%) after 20 days (p = 0.001), as did participants with >1 warning signs (≈40%) compared with participants without warning signs (≈85%) after 15 days (p<0.001). Participants with higher education had a faster recovery of HRQOL than did participants with less education (p<0.001).
We used a Cox regression analysis ( Table 2) to identify factors associated with HRQOL recovery (model: proportionality confirmed; mean variance inflation factor = 1.09, all variables variance inflation factor <1.21; final model χ 2 37.8, p<0.001; McFadden pseudo-R 2 = 0.11). Recovery rates were higher for men than for women (hazard ratio [HR] 1.87; p = 0.036), patients with more education (HR 2.06; p = 0.042), and patients with no severe symptoms (HR 2.82; p = 0.001). In the first 15 days of disease, dengue patients without skin ache had a 63% lower likelihood (HR 0.37; p = 0.002) and patients without scaling had a 67% lower likelihood (HR 0.33, p = 0.038) of recovering to baseline HRQOL.
Conclusions
Dengue significantly reduces HRQOL beyond the febrile phase. Mobility, pain, and usual activities were the most affected domains, consistent with previous studies (8, 12) . The proportion of patients reporting problems remained stable among patients with persistent symptoms of dengue. HRQOL decreased abruptly during the febrile phase; most patients then steadily recovered, with some exceptions for those who had not reached baseline HRQOL at 6 months. Other studies have found larger reductions of HRQOL than we found; mean EQ-VAS score was 7 for children 0-14 years of age in Cambodia (13) and 10 for hospitalized patients and 20 for ambulatory patients in Brazil (7) . Our findings were comparable to those of Armien et al. (14) in Panama (EQ-VAS 35.2 for children; 31.9 for adults). Female sex was significantly associated with dengue severity in our study, and education (a proxy for socioeconomic status) might be a protective factor. We found skin symptoms to be associated with a faster recovery, possibly because of a lower inflammatory or immune response (15) .
Our findings are subject to limitations: an adultsonly sample; limited socioeconomic characterization of participants; lack of data about previous DENV infections; limitations of the EQ-5D-3L instrument; possible recall bias for baseline HRQOL; response-, recalibration-, and reconceptualization responseshift biases; and a relatively small sample of patients with laboratory-confirmed dengue. Despite these limitations, our findings are relevant for clinical practice and health services research and can help researchers and other stakeholders improve estimates of dengue effects. 
